FIELD: molecular biology, biochemistry, immunology. SUBSTANCE: recombinant antibody reacts specifically with protein p55 of Tac-receptor of human interleukin-2 (IL-2). The indicated antibody inhibits binding of IL-2 with IL-2-receptor on human T-cells and shows affinity to IL-2 receptor above 108M-1. In consists of light and heavy chains and has sites that determine complementarity (CDRs). Invention proposes also polynucleotides containing a sequence encoding carcass sites and sites determining complementarity of binding with antigen (CDRs). Also, invention proposes methods of preparing heavy and/or light chains of recombinant antibody. Invention can be used for preparing recombinant DNA and nonimmunogenic monoclonal antibodies for preparing new therapeutic agents. EFFECT: improved method of preparing. 11 cl, 10 dwg, 1 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
HUMAN IMMUNOGLOBULIN SHOWING SPECIFICITY TO HUMAN PROTEIN L-SELECTIN | 1993 |
|
RU2151612C1 |
RECOMBINANT ANTIBODY IL4 USED FOR TREATMENT OF DISORDERS ASSOCIATED WITH FUNCTION OF IL4 | 1994 |
|
RU2162711C2 |
IMPROVED ANTI-IGE-ANTIBODY (VARIANTS) AND METHOD FOR IMPROVING POLYPEPTIDES | 1998 |
|
RU2242515C2 |
HUMANIZED ANTIBODIES THAT RECOGNIZE VEROTOXIN II AND CELL LINE PRODUCING THEREOF | 1999 |
|
RU2217166C2 |
NOVEL ANTI-IL13 ANTIBODIES AND USE THEREOF | 2004 |
|
RU2487887C2 |
OX40L ANTIBODIES AND METHODS FOR USING | 2006 |
|
RU2426744C2 |
FcγRIIB RECEPTOR ANTIBODIES AND APPLICATION THEREOF | 2005 |
|
RU2404991C2 |
HUMANISED ANTI-TGF-BETA-ANTIBODY | 2005 |
|
RU2386638C2 |
HUMANIZED ANTIBODY THAT SHOWS CAPACITY TO BIND ErbB2 AND BLOCK ACTIVATION OF ErbB2 RECEPTOR BY LIGAND (VARIANTS) AND COMPOSITION FOR USING IN CANCER TREATMENT COMPRISING THIS ANTIBODY | 2000 |
|
RU2270029C2 |
ANTI-CXCR4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | 2014 |
|
RU2675516C2 |
Authors
Dates
1999-02-10—Published
1989-12-28—Filed